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TABLE 1. Time trends in number of patients receiving only young or old fresh-frozen plasma
Year Only young FFP* Mixed FFP Only old FFP* Total
2004 2 (2.7%) 1 (1.4%) 71 (96%) 74
2005 0 (0%) 4 (1.1%) 365 (99%) 369
2006 5 (1.2%) 20 (4.8%) 390 (94%) 415
2007 120 (27%) 88 (20%) 243 (54%) 451
2008 283 (57%) 121 (25%) 89 (18%) 493
2009 28 (18%) 25 (16%) 103 (66%) 156
FFP, Fresh-frozen plasma. *Only young and only old defined according to van Straten and colleagues1 at a cutoff of
323 days. Figures represent number of patients and percentages (in parentheses) of the total number of FFP recip-
ients in that year.
Letters to the EditorReply to the Editor:
My colleagues and I appreciate the
comments by Lin and colleagues
regarding potential issues that may
influence outcomes in pexelizumab-
treated patients. Their hypothesis
that pexelizumab may cause platelet
aggregation, however, is not sup-
ported by the literature. We note
that their reference 3 (Røger and col-
leagues) actually suggested that in-
hibiting the terminal complement
cascade with a molecule such as pex-
elizumab might inhibit platelet ag-
gregation. The suggestion of Lin
and colleagues that this compound’s
cardioprotective effect may depend
on the presence of adequate antith-
rombotic therapy is an interesting
but unproven hypothesis. Unfortu-
nately, Lin and colleagues’ sugges-
tion that large amounts of heparin
may achieve longer activated clotting
times to suppress thrombin activity is
also not supported by the literature.1
We also disagree that as time passes,
heparin-bonded circuits may replace
the traditional bypass circuits, be-
cause the literature is equivocal that
reducing perioperative heparin im-
proves safety in cardiac surgical pa-
tients. In fact, there is literature
suggesting that providing even more
systemic heparin might be important
in producing less bleeding in cardiac
surgical patients.2,3
Lin and colleagues is suggested that
we reanalyze the Pexelizumab for Re-
duction of Infarction and Mortality in
Coronary Artery Bypass Graft Sur-
gery data with regard to the use of
heparin-bonded perfusion circuits,
presumably as a surrogate for total
heparin dose, to test their hypothesis.
We have reviewed the data from the
Pexelizumab for Reduction of Infarc-
tion and Mortality in Coronary Artery
Bypass Graft Surgery II trial, in which
27% of the patients were operated on
with heparin-bonded circuits. The pri-
mary end point did not differ between
pexelizumab and placebo groups (rel-
ative risk, 1.02; P ¼ .9319). HeparinThe Journaldosing was not captured in the case re-
port forms.
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STORAGE TIME OF
TRANSFUSED PLASMA ON
EARLYAND LATE MORTALITY
AFTER CORONARYARTERY
BYPASS GRAFTING’’
To the Editor:
Plasma from blood donors is frozen
and stored at30C for a maximum of
2 years. van Straten and colleagues1
recently reported a 3 times increased
30-day mortality after coronary artery
bypass grafting if patients received
fresh-frozen plasma (FFP) that had
been stored for more than 323 days
(old) compared with FFP that hadof Thoracic and Cardiovascular Surgebeen stored for a shorter time (young).
If longer storage of FFP is truly inde-
pendently associated with a higher
mortality, we would need to consider
changing the regulations on storage
times of FFP. However, before jump-
ing to this conclusion, one needs to
carefully consider alternative explana-
tions for the observed association, such
as potential biases and confounding.
The design of the study, a cohort
among consecutive patients undergo-
ing coronary artery bypass grafting in
a period of 10 years, was well chosen,
because the choice to transfuse old or
young FFP is random. Patients who
have received old FFP and patients
who have received young FFP can
therefore be compared as if from a ran-
domized trial. Table 1 in the report can
be used to check whether the random-
ization was successful. Unfortunately,
there are several remarkable differ-
ences between the intervention
groups, such as the number of patients
who underwent reexploration (young
FFP 36% vs old FFP 25%) and plate-
let transfusion (young FFP 0.29 units
vs old FFP 0.42 units). Therefore, we
conclude that proper randomization
was not achieved.
There are several possible explana-
tions for unequal distribution of prog-
nostic factors across the intervention
groups. Changes in techniques to pro-
duce and store FFP, such as leucode-
pletion since 2001 and the male-only
plasma measure since 2007, have all
affected the storage times of FFP dur-
ing the 10-year period of the study.
Therefore, although the choice tory c Volume 142, Number 2 473
Letters to the Editortransfuse old or young FFP is random
at any given time, the probability of
receiving old or young FFP varied
over the study period. In addition, dur-
ing the 10-year period, operation tech-
niques, transfusion strategies, and
supportive care have also changed.
As a result, the increased survival of
patients receiving young FFP might
not be related to the properties of the
transfused plasma but rather to the im-
provements in operative, supportive,
or nursing strategies, which happen
to temporally coincide with the proba-
bility of receiving young FFP.
We examined time trends in FFP
storage time in The Netherlands by
documenting the storage time of FFP
between 2004 (a new transfusion infor-
mation system was introduced in our
hospital in 2004) and 2009 in the
Leiden University Medical Center.
Table 1 shows that the number of pa-
tients who have received only old FFP
and only young FFP has changed sig-
nificantly during these years. Similar
differencesmay form an alternative ex-
planation for the association between
old FFP and mortality as reported by
van Straten and colleagues. We agree
with the authors that additional studies
are necessary to resolve this issue.
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‘‘NO-TOUCH’’ HARVESTING
AND VASAVASORUM
To the Editor:
Dreifaldt and colleagues1 carried
out an elegant image study to evaluate
the impact of vein graft harvesting
technique on the structure and func-
tion of vasa vasorum. The total area
of vasa vasorum in vein grafts har-
vested with the conventional tech-
nique was significantly reduced in
both the media and the adventitia
compared with vein grafts harvested
with the ‘‘no-touch’’ technique that
preserved an intact vasa vasorum,
whereas the conventional technique
did not.1 These findings corroborate
Dashwood and colleagues’2 hypothe-
sis that vasa vasorum preservation
could represent one of the mecha-
nisms underlying the possible im-
proved patency of saphenous vein
grafts harvested with this technique.2
We would like to share with the au-
thors some thoughts and speculations
based on evidence from the literature.
Three processes are responsible for
vein graft failure: thrombosis, intimal
hyperplasia, and accelerated athero-
sclerosis, which contribute to graft
failure. Studies have shown that
perioperative antiplatelet therapy can
reduce early thrombosis and graft fail-
ure. The ‘‘no-touch’’ technique for har-
vesting grafts may be effective in
preventing disruption to the endothelial
layer and subsequent intimal hyperpla-
sia and graft loss,3 but at least one
apparent paradox has to be clarified
about human saphenous veinvasavaso-
rum. This apparent paradox is based on
the well-known fact that absence of
vasa vasorum is a probable protection
against intramyocardial arteries and
left thoracic artery atherosclerosis.
Recent evidence has shown no clini-
cal disadvantages, andevenadvantages,
of not replacing angiographically pris-
tine grafts at long-term follow-up.Mea-
surements of nitric oxide release of old
saphenous vein grafts, when angio-
graphically pristine, are equal to thatardiovascular Surgery c August 2011of native saphenous veins. These find-
ings support the recent clinical observa-
tions that long-term angiographically
disease-free vein grafts are biologically
privileged.4
The vasa vasorum form a network
of microvasculature to supply oxygen
and nutrients to the outer layers of the
arterial wall. The expansion of the
vasa vasorum to the second order is
associated with neovascularization re-
lated to progression of atherosclerosis.
It was shown that, when arterial grafts
are used in coronary bypass surgery
(eg, internal thoracic artery and right
gastroepiploic artery), the poorly de-
veloped vasa vasorum is related to
better patency.5 However, in saphe-
nous vein graft, the preservation of
vasa vasorum can be associated with
reduction of graft failure.1,2 As al-
readymentioned, is this fact a paradox
or are there functional differences be-
tween arteries and veins? In other
words, the presence of vasa vasorum
in arteries ‘‘facilitates’’ atherosclero-
sis and, on the other hand, its presence
‘‘protects’’ against the same process
of atherosclerosis? That would be an
important point to be investigated.
There are histologic and image
studies showing the human saphenous
structures preservation by using the
‘‘no-touch’’ harvesting. In dealing
with studies on the patency of saphe-
nous vein, Dashwood and colleagues2
provided interesting information about
increasing the human saphenous vein
graft patency in the long-term. How-
ever, the number of patients studied
is small and large trials are still needed
to prove the superiority of grafts har-
vested by the no-touch technique.
The discussion on human saphe-
nous vein harvesting can repeat the in-
ternal thoracic artery skeletonization
saga. In the end, the results of coro-
nary artery bypass grafting with sa-
phenous veins would be similar. It is
necessary to emphasize an important
salutary bias toward the ‘‘no-touch’’
technique, which in principle implies
obsessive care in harvesting the veins.
